Our spiky young man Li Yi
Release time:
2023-05-04
Li Yi
Age: 27 Years Old
Position: Jianfeng Pharmaceutical Quality Department
Entry Time: November 2021
Talk about our "Master Brother"
In QA Department of Jianfeng Pharmaceutical, there is a "Master Brother" that everyone loves ". Don't get me wrong, our master brother is not the omnipotent Sun Dasheng in "Journey to the West", but a gentle and generous post -95 girl-Li Yi. You may wonder how such a girl can be called a "master elder brother". Speaking of the reason, there is still a short story.
In the first quarter of each year, QA has to complete the annual quality report of each product in the previous year, so this is also the busiest time in the department. During this time, on-site QA spent all its time drafting and reviewing product annual reports, in addition to supervising the production site and reviewing records. "Senior Brother" is the system QA, responsible for change management and other work, she has been eager to help everyone after completing the information related to the change in the annual report, now check the registration information, later help to draw a trend chart ...... Busy before and after also completely did not leave their work. One day, we were chatting in the cafeteria over dinner, and when we talked about "a few masters and apprentices on the road to the West, if you choose one, who do you intend to be", someone said, "It is estimated that everyone would want to be the second senior brother of the group. But if we compare our department to the scripture-learning team, then Li Yi must be the master brother with the highest contribution value to our 'road to the scripture-learning." Everyone nodded in agreement. Coincidentally, Li Yi's WeChat avatar happens to be Sun Wukong. From then on, we began to affectionately call Li Yi "Master Brother!
Sun Wukong has a golden cudgel, and our "master elder brother" also has a treasure, which is her "Technical Guidelines for Post-marketing Chemical Pharmaceutical Change Research". On weekdays, she can always be seen holding the book and reading it carefully. She laughed and said that the guiding principles are her work manual. If someone comes to ask what research needs to be done for a change, the "big brother" will surely give him a satisfactory answer. Someone asked "Big Brother" why he was so fond of that guiding principle. "Senior Brother" said, "I often look at the new ones. You see, it has been more than ten years since GMP was released, but not everyone in our department will take it out and look at it again. After reading the new regulations, studying the new guidelines, and then going back to see GMP, there will definitely be new insights into a certain clause."
Yes, in recent years, new laws and regulations, departmental rules and industry guidelines have emerged one after another in the pharmaceutical industry, especially in the area of drug change management. Before that, the "Drug Administration Law" and "Post-marketing Drug Change Management Measures" determined the keynote of drug change management, and after that, various documents such as various change guidelines and provincial bureau change communication rules clearly changed the specific management mode. "Senior Brother" loves learning and will discuss certain events with us from time to time. Everyone checks laws and regulations, reads documents, expresses their own opinions and quotes classics, thus arousing the learning atmosphere of the whole department.
Lively and enthusiastic, studious and diligent, and thoughtful, "Master Brother" shows us the best of contemporary young people with her words and deeds. At the moment, our "master elder brother" is frowning in front of his desk again, thinking carefully. I think we will enter the next seminar. (lisa liao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page